XORTX Therapeutics Inc.
XRTX.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -3.43% | 0.40% | 1.25% | 1.66% | -0.97% |
| Depreciation & Amortization | -16.18% | -16.32% | -26.13% | -13.44% | 139.62% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -47.20% | -57.83% | -56.01% | -53.11% | -46.37% |
| Operating Income | 47.20% | 57.83% | 56.01% | 53.11% | 46.37% |
| Income Before Tax | -53.53% | 90.09% | 79.69% | 51.15% | 72.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -53.53% | 90.09% | 79.69% | 51.15% | 72.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.53% | 90.09% | 79.69% | 51.15% | 72.04% |
| EBIT | 47.20% | 57.83% | 56.01% | 53.11% | 46.37% |
| EBITDA | 39.91% | 58.26% | 56.42% | 53.38% | 47.47% |
| EPS Basic | -21.23% | 99.12% | 88.21% | 67.00% | 78.53% |
| Normalized Basic EPS | -21.24% | 99.11% | 88.21% | 66.99% | 78.54% |
| EPS Diluted | -20.48% | 99.12% | 88.16% | 66.86% | 78.40% |
| Normalized Diluted EPS | -21.24% | 99.11% | 88.21% | 66.99% | 78.54% |
| Average Basic Shares Outstanding | 45.25% | 36.17% | 34.04% | 31.54% | 33.89% |
| Average Diluted Shares Outstanding | 45.25% | 36.17% | 34.04% | 31.54% | 33.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
